Eli Lilly's oral GLP-1RA maintains weight loss from injectable drugs [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
During the 52-week Phase III ATTAIN-MAINTAIN study (NCT06584916), the weight loss pill offered significant weight maintenance benefits over placebo when used as an adjunctive therapy alongside a healthy diet and physical activity – meeting the trial's primary endpoint. This impact was seen in patients who had previously received 72 weeks of treatment with the highest dose of either Lilly's injectable weight loss drug, Zepbound (tirzepatide), or Novo Nordisk's competitor GLP-1RA, Wegovy (semaglutide), who were enrolled from the SURMOUNT-5 head-to-head trial (NCT05822830). The average weight gain of patients transitioned from Wegovy to orforglipron was 0.9kg, while those transitioning from Zepbound to orforglipron experienced a 5kg weight gain after 52 weeks of maintenance therapy. The average weight of patients transitioned from Wegovy and Zepbound before the 52-week maintenance period was 95kg and 90.9kg, respectively, with the average weight after being 95.9kg in both cohorts.
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- This is how exposed European Big Pharma is to the U.S. [MSNBC.com]MSNBC.com
- UBS Reiterates Neutral on Novo Nordisk A/S (NVO) Despite Wegovy Dose Progress [Yahoo! Finance]Yahoo! Finance
- Prediction: 1 Healthcare Giant Set to Soar in 2026 [Yahoo! Finance]Yahoo! Finance
- Obesity pill race heats up [CNBC]CNBC
- Eli Lilly Obesity Pill Maintains Weight Loss After Wegovy, Zepbound [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website